Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved.
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | artículo biblioteca |
Language: | English |
Published: |
Elsevier
2014
|
Subjects: | Rift Valley Fever virus, MVA vaccine, Sheep experimental infection, GnGc glycoproteins, Virus shedding, |
Online Access: | http://hdl.handle.net/20.500.12792/5007 http://hdl.handle.net/10261/290025 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-inia-es-10261-290025 |
---|---|
record_format |
koha |
spelling |
dig-inia-es-10261-2900252023-02-17T08:26:37Z Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs Busquets, N. Lorenzo Alguacil, Gema López-Gil, E. Rivas, R. Solanes, D. Galindo-Cardiel, I. Abad, F. X. Rodríguez, F. Bensaid, A. Warimwe, G. Gilbert, S. C. Domingo, M. Brun Torres, Alejandro Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved. 2023-02-17T08:26:37Z 2023-02-17T08:26:37Z 2014 artículo Antiviral Research 108: 165-172 (2014) 0166-3542 http://hdl.handle.net/20.500.12792/5007 http://hdl.handle.net/10261/290025 10.1016/j.antiviral.2014.05.020 1872-9096 en none Elsevier |
institution |
INIA ES |
collection |
DSpace |
country |
España |
countrycode |
ES |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-inia-es |
tag |
biblioteca |
region |
Europa del Sur |
libraryname |
Biblioteca del INIA España |
language |
English |
topic |
Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding |
spellingShingle |
Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding Busquets, N. Lorenzo Alguacil, Gema López-Gil, E. Rivas, R. Solanes, D. Galindo-Cardiel, I. Abad, F. X. Rodríguez, F. Bensaid, A. Warimwe, G. Gilbert, S. C. Domingo, M. Brun Torres, Alejandro Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
description |
The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved. |
format |
artículo |
topic_facet |
Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding |
author |
Busquets, N. Lorenzo Alguacil, Gema López-Gil, E. Rivas, R. Solanes, D. Galindo-Cardiel, I. Abad, F. X. Rodríguez, F. Bensaid, A. Warimwe, G. Gilbert, S. C. Domingo, M. Brun Torres, Alejandro |
author_facet |
Busquets, N. Lorenzo Alguacil, Gema López-Gil, E. Rivas, R. Solanes, D. Galindo-Cardiel, I. Abad, F. X. Rodríguez, F. Bensaid, A. Warimwe, G. Gilbert, S. C. Domingo, M. Brun Torres, Alejandro |
author_sort |
Busquets, N. |
title |
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
title_short |
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
title_full |
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
title_fullStr |
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
title_full_unstemmed |
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs |
title_sort |
efficacy assessment of an mva vectored rift valley fever vaccine in lambs |
publisher |
Elsevier |
publishDate |
2014 |
url |
http://hdl.handle.net/20.500.12792/5007 http://hdl.handle.net/10261/290025 |
work_keys_str_mv |
AT busquetsn efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT lorenzoalguacilgema efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT lopezgile efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT rivasr efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT solanesd efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT galindocardieli efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT abadfx efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT rodriguezf efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT bensaida efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT warimweg efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT gilbertsc efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT domingom efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs AT bruntorresalejandro efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs |
_version_ |
1767603037944152064 |